EMA Refused: Atropine sulfate FGK (atropine sulfate) — FGK Representative Service GmbH

View source ↗

Summary

EMA refused the marketing authorization for atropine sulfate FGK for myopia (decision date 18 September 2025).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myopia

Drugs mentioned

• Atropine sulfate FGK (atropine sulfate)

Snippet

Status: Refused. Therapeutic area: Myopia. MAH: FGK Representative Service GmbH. Decision date: 18/09/2025